drugset
drugset / Trial / NCT03429998

Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia

NCT03429998 ↗

Phase 3 Completed 9 enrolled Hospital General Universitario Gregorio Marañon
Non-randomizedParallel-groupOpen-labelTreatment

Summary

An open-label, prospective phase III study to compare the efficacy and safety of administering evolocumab versus treatment with LDLapheresis in patients with familial hypercholesterolemia and high cardiovascular risk.

Timeline

Start
2017-04-01
Primary completion
2018-01-28
Completion
2018-01-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Evolocumab Monoclonal antibody 140 mg Subcutaneous

Indications

familial hypercholesterolemia